For decades, cancer drug developers have focused on inhibition. Now, a GV-backed startup is eyeing activation - Endpoints News
endpts.comSubmitted by endpointsnews6292 in health
One of the backbones of cancer medicine is shutting down key cancer-driving pathways to kill tumor cells. But for years, researchers have noticed hyperactivation of certain signals in these pathways can lead to the same result. Researchers from Bill Sellers’ …